NMR Studies of Streptozotocin Effects on Rat Plasma Fatty Acids

Abstract

Abstract:

Lipid metabolic dysfunction is a well-accepted risk factor of diabetic complications. Cardiovascular complications of diabetes are the leading cause of diabetic death. In this work, the dynamic changes in plasma levels of unsaturated fatty acids (UFAs) were measured, using diffusion-edited ¹H NMR spectroscopy, in a rat model of streptozotocin (STZ)-induced type 1 diabetes. The results showed that STZ treatment induced elevated UFAs and monounsaturated fatty acids levels in the plasma, and the dynamic changes of fatty acid ratios correlated well with the progression of diabetes. It was proposed that plasma levels of UFAs might be more sensitive indicators for development of type 1 diabetes than clinical lipid screening indices, such as triglyceride (TG) and high-density lipoprotein (HDL) levels.

Key words: NMR, plasma, fatty acid, streptozotocin

CLC Number:

O482.53

XU Wen-xin1,2, AN Yan-peng1,2, TANG Hui-ru1*. NMR Studies of Streptozotocin Effects on Rat Plasma Fatty Acids[J]. Chinese Journal of Magnetic Resonance.

References

[1] Maier L M. Genetic susceptibility to type 1 diabetes[J]. Curr Opin Immunol, 2005, 17(6): 601-608.

[2] Garcia M J, McNamara P M, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study[J]. Diabet, 1974, 23(2): 105-111.

[3] Kleinman J C, Donahue R P, Harris M I, et al. Mortality among diabetics in a national sample[J]. Am J Epidemiol, 1988, 128(2): 389-401.

[4] Krolewski A S, Czyzyk A, Janeczko D, et al. Mortality from cardiovascular diseases among diabetics[J]. Diabetologia, 1977, 13(4): 345-350.

[5] American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabet Care, 2004, 27 (Suppl 1): S5-S10.

[6] Roglic G, Unwin N, Bennett P H, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000[J]. Diabet Care, 2005, 28(9): 2 130-2 135.

[7] Maria P S, Ronald B G. Lipid management in type 2 diabetes[J]. Clin Diabet, 2006, 24(1): 27-32.

[8] Georg P, Ludvik B. Lipids and diabetes[J]. J Clin Basic Cardiol, 2000, 3(3): 159-162.

[9] Haffner S M, Stern M P, Hazuda H P, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?[J]. J Am Med Assoc, 1990, 263(21): 2 893-2 898.

[10] He Q H, Ren P P, Kong X F, et al. Comparison of serum metabolite compositions between obese and lean growing pigs using an NMR-based metabonomic approach[J]. J Nutri Biochem, 2012, 23(2): 133-139.

[11] Xu W X, Wu J F, An Y P, et al. Streptozotocin-induced dynamic metabonomic changes in rat biofluids[J]. J Proteome Res, 2012, DOI:10.1021/pr300280t.

[12] Zhang X Y, Wang Y L, Hao F H, et al. Human serum metabonomic analysis reveals progression axes for glucose intolerance and insulin resistance statuses[J]. J Proteome Res, 2009, 8(11): 5 188-5 195.

[13] Mary K C, Shawn O F. Biochemistry(5th ed)[M]. New York: Brooks, 2006.

[14] Serkova N J, Jackman M, Brown J L, et al. Metabolic profiling of livers and blood from obese Zucker rats[J]. J Hepato, 2006, 44(5): 956-962.

[15] Lewis L A. Blood lipids and lipoproteins: quantitation, composition, and metabolism.[J]. Clinic Chem, 1973, 19(6): 690-691.

[16] Rakieten N, Rakieten M L.Nadkarni M V. Studies on the diabetogenic action of streptozotocin (NSC-37917)[J]. Cancer Chemother Rep, 1963, 29(1): 91-98.

[17] Elsner M, Guldbakke B, Tiedge M, et al. Relative importance of transport and alkylation for pancreatic beta-cell toxicity of streptozotocin[J]. Diabetologia, 2000, 43(12): 1 528-1 533.

[18] Zhang S C, Gowda G A N, Asiago V, et al. Correlative and quantitative ¹H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats[J]. Anal Biochem, 2008, 383(1): 76-84.

[19] Junod A, Lambert A E, Stauffacher W, et al. Diabetogenic action of streptozotocin: relationship of dose to metabolic response[J]. J Clin Invest, 1969, 48(11): 2 129-2 139.

[20] Fan T W M. Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures[J]. Prog Nucl Magn Reson Spect, 1996, 28(1996): 161-219.

[21] Nicholson J K, Foxall P J, Spraul M, et al. 750 MHz ¹H and ¹H-¹³C NMR spectroscopy of human blood plasma[J]. Anal Chem, 1995, 67(5): 793-811.

[22] Beckwith-Hall B M, Thompson N A, Nicholson J K, et al. A metabonomic investigation of hepatotoxicity using diffusion-edited ¹H NMR spectroscopy of blood serum[J]. Analyst, 2003, 128(7): 814-818.

[23] Maritim A C, Sanders R A.Watkins J B. Diabetes, oxidative stress, and antioxidants: a review[J]. J Biochem Mol Toxic, 2003, 17(1): 24-38.

[24] Biddinger S B, Miyazaki M, Boucher J, et al. Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein1c[J]. Diabet, 2006, 55(7): 2 032-2 041.

[25] Boyko E J, Leonetti D L, Bergstrom R W, et al. Low insulin secretion and high fasting insulin and C-peptide levels predict increased visceral adiposity. 5-year follow-up among initially nondiabetic Japanese-American men[J]. Diabet, 1996, 45(8): 1 010-1 015.

[26] Bj-rntorp P. Regional fat distribution: implications for type II diabetes[J]. Int J Obes Relat Metab Disord, 1992, 16(Suppl 4): S19-S27.

[27] Jane E A. Fatty acid composition of fat depots in wintering Canada geese[J]. Wilson Bull, 1993, 105(2): 339-347.